Two Roads Diverge For Mylan: Teva Or Perrigo

Teva announced a proposal to acquire Mylan for $82 per share, or roughly $40 billion, putting Mylan’s independence and a proposal to acquire OTC drug specialist Perrigo in question. Adding to the uncertainty, Perrigo rejected Mylan’s offer after market close.